JingCai Intelligence Secures Tens of Millions in Pre-A Funding to Advance Musculoskeletal (MSK) Digital Therapeutics
VCBeat has learned that Beijing Jingcai Intelligent Technology Co., Ltd. (“Jingcai Intelligent”) recently announced the completion of its Pre-A financing round, raising tens of millions of yuan.This round of financing was led by the China United Capital-Luxin Venture Capital Fund, with follow-on investments from Zhangjiagang Shazhou Sci-Tech Innovation and Jinxin Capital. Qiangyun Capital served as the exclusive financial advisor.The proceeds from this financing round will be used to expand new business lines and support product R&D in areas such as digital rehabilitation, occupational musculoskeletal health, early developmental interventions for children’s health, and smart elderly care, as well as to further expand the team. This marks another recognition by specialized healthcare funds and industrial strategic investors, following the company’s first-round investment from Danlu Capital last June.
Musculoskeletal pain is a global health concern. Particularly in modern society, an increasing number of people are experiencing musculoskeletal pain due to prolonged sitting, lack of exercise, overexertion, and improper exercise posture. Beijing Jingcai Intelligent Technology Co., Ltd. focuses on digital rehabilitation and the prevention and treatment of musculoskeletal injuries, collaborating closely with leading medical institutions in China.As of February this year, the Jingcai Intelligent series products have rapidly expanded in the market, achieving a cumulative total of 150,000 intelligent assessments and training sessions.After its business model was validated at scale, Jingcai Intelligent has achieved profitability, making it one of the few profitable companies in the digital therapeutics sector.
Jingcai Intelligence is committed to creating an intelligent healthcare environment, focusing on human-centric smart services.Leveraging our independently developed 3D digital human engine, we have created a suite of products including intelligent motor function assessment, smart training, and assisted diagnosis and treatment, establishing a closed-loop system for “assessment–evaluation–training.”The company's products leverage multiple technologies, including multimodal fusion, intelligent recognition, and big data analytics.Enable precise assessment of individuals without wearables or markers, quantify evaluation results to improve efficiency, and leverage a sports health knowledge graph with an interdisciplinary expert system to automatically generate assessment reports and personalized exercise prescriptions., catering to personalized needs.
Mr. Li Yao, founder of Jingcai Intelligence, has many years of management and marketing experience in the digital sector. He previously served as a core member of the management team at a unicorn technology company and possesses both serial entrepreneurial experience and executive management experience with publicly listed companies. The core team members include renowned experts in computer vision and wearable technology in China, specialists in digital twin technology, and senior professionals in the fields of biomechanics and sports rehabilitation.
Regarding this financing round, Mr. Li Yao, founder of Jingcai Intelligence, stated: We extend our gratitude to China Everbright Capital & Luxin Venture Capital, Zhangjiagang Shazhou Sci-Tech Innovation, Jinxin Capital, and our existing shareholder Danlu Capital for their investment and support. We share a strong confidence in the development of MSK (musculoskeletal) digital therapeutics in China, as digital-intelligent healthcare represents an inevitable trend for the industry’s future. In the rapidly growing market of musculoskeletal pain management and sports health, North America already boasts several unicorn companies. Within the next 3–5 years, China will undoubtedly see the emergence of multiple outstanding unicorns. Beijing Jingcai Intelligent Technology Co., Ltd. will build its competitive moat through a four-dimensional integrated strategy encompassing digital-intelligent operations, smart hardware, AI algorithms, and diversified commercial scenarios, thereby continuing to lead the industry forward.
Mr. Gao Wenbo, Partner at China United Capital-Luxin Fund, the lead investor in this round of financing, stated: We maintain a strong focus on both the digitalization and intelligent transformation of industries, as well as the healthcare sector, continuously tracking and investing in outstanding teams and enterprises within these fields, including frontier areas such as neuromorphic computing and brain-computer interfaces. The team at Beijing Jingcai Intelligent Technology Co., Ltd. effectively integrates these two domains. Furthermore, founder Li Yao possesses robust capabilities in establishing closed-loop business models, enabling the rapid translation of technology into industrial applications. This aligns perfectly with our investment thesis centered on cross-disciplinary innovation.
As strategic resource investors, Zhangjiagang Shazhou Sci-Tech Innovation and Zhangjiagang Jinxin Capital stated: New healthcare is a key industry that Zhangjiagang City has prioritized for introduction and development. Jingcai Company’s intelligent sports medicine and rehabilitation equipment project aligns closely with the city’s industrial development direction. The company boasts a heavyweight team of expert technicians, possesses strong independent R&D capabilities, and demonstrates excellent technology that reaches or approaches international advanced levels; moreover, its products have been validated through market practice. We are firmly convinced that the project holds very promising prospects for future development.
As the exclusive financial advisor for this round of financing, Mr. Sun Bin, Vice President of Qiangyun Capital, stated: There is a severe shortage of professionals in China’s rehabilitation therapy sector, and digital approaches hold significant potential for application in musculoskeletal (MSK) rehabilitation. Beijing Jingcai Intelligent Technology Co., Ltd. boasts a solid technological foundation, a highly capable team, a well-established product portfolio, and a closed-loop business model. We are highly optimistic about the expertise demonstrated by Jingcai Intelligent’s team, led by Mr. Li, in the fields of digital health and medical rehabilitation, particularly their strong market promotion capabilities. We are committed to providing long-term support to accompany Jingcai Intelligent’s growth.
Beijing Jingcai Intelligent Technology Co., Ltd. is an AI + healthcare enterprise founded by senior executives from internationally renowned technology companies and distinguished scholars from prestigious universities such as Tsinghua University and Beihang University. With years of technical expertise in intelligent sensing, precise motion measurement, computer vision, and virtual simulation, and leveraging its robust R&D capabilities and strategic market presence, the company is committed to becoming a leader in the digital therapeutics industry for musculoskeletal (MSK) conditions.
The China United Capital-Luxin Fund was established in 2018 as a joint initiative by China United Capital Group and Luxin Venture Capital. Leveraging the respective strengths of both parties and fully utilizing resources from listed companies and related industries, the fund focuses on national strategic emerging industries by investing in innovative frontier technology projects. Key investment areas include robotics, artificial intelligence, virtual reality, augmented reality, intelligent vehicles, the Internet of Things (IoT), big data and cloud computing, digital healthcare, biopharmaceuticals, and medical devices and services.
The Zhangjiagang Shazhou Sci-Tech Innovation Fund was jointly established by the Zhangjiagang Municipal Science and Technology Bureau and the Zhangjiagang Innovation Investment Group. Adopting a direct investment strategy, the fund focuses primarily on emerging industrial chain projects in specialized semiconductors, biopharmaceuticals and high-end medical devices, new energy, and the digital economy. Healthcare and high-end medical devices are among its key areas of interest. By attracting a batch of high-potential, high-quality projects characterized by advanced industrialization, strong market recognition, and high technological content, the fund aims to inject “fresh vitality” into Zhangjiagang’s industrial development and drive industrial transformation and upgrading.
Zhangjiagang Jinxin Capital Investment Management Co., Ltd., with a registered capital of RMB 1 billion, is primarily engaged in investment and financing, capital operations, and industrial incubation. Focusing on the development of the “3+N” industrial clusters in the park and towns, the company aims to establish an industrial capital information window for these areas. It actively leverages its capital allocation function, flexibly employs various investment models to guide social capital into park and town industries, facilitates internal and external integration, channels and supplements capital flows, and uses investment to attract resources. By strengthening, supplementing, extending, and reinforcing industrial chains, the company promotes both inward introduction and outward expansion, leading state-owned capital and enterprises in the park and towns toward broader development opportunities.
Qiangyun Capital is a boutique investment bank specializing in the healthcare and medical sector, with offices in Beijing, Shanghai, and Hangzhou. It is renowned in the industry for its high efficiency, high success rate, and comprehensive services. The Qiangyun Capital team comprises professionals from boutique investment banks, accounting firms, biotechnology companies, and other related fields. Since its establishment, the firm has facilitated hundreds of millions of RMB in financing for its clients, covering areas such as diagnostics, medical devices, digital health, biotechnology, new drug R&D, healthcare services, innovative payment solutions, and CXO.